In a recent letter to the editor, the author rightly highlighted the potential interference of contrast media (CM) used in imaging studies with clinical laboratory tests, proposing an algorithm to manage these interactions.1 We commend the author for this effort, but we believe it is crucial to address the underlying assumptions regarding the safety of intravenous contrast media, particularly its association with nephrotoxicity. Nephrotoxicity from intravenous iodine-based media remains a debated issue, with diverging views in the literature. We aim to expand on those concerns and hereby present a brief review of the current evidence on contrast-associated acute kidney injury (CA-AKI), or post-contrast acute kidney injury (PC-AKI), as well as our view of the evolving guidelines regarding its use in patients with kidney injury.

Clique aqui para aceder ao artigo completo (em inglês).